Vertex Pharmaceuticals (NASDAQ:VRTX) CMO Sells $785,250.00 in Stock

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) CMO Carmen Bozic sold 1,745 shares of the stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $450.00, for a total transaction of $785,250.00. Following the transaction, the chief marketing officer owned 21,015 shares in the company, valued at $9,456,750. The trade was a 7.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Carmen Bozic also recently made the following trade(s):

• On Tuesday, May 12th, Carmen Bozic sold 6,988 shares of Vertex Pharmaceuticals stock. The shares were sold at an average price of $450.00, for a total transaction of $3,144,600.00.
• On Friday, March 13th, Carmen Bozic sold 2,329 shares of Vertex Pharmaceuticals stock. The shares were sold at an average price of $481.79, for a total transaction of $1,122,088.91.

Vertex Pharmaceuticals Price Performance

Shares of NASDAQ VRTX opened at $445.04 on Friday. Vertex Pharmaceuticals Incorporated has a one year low of $362.50 and a one year high of $507.92. The firm’s 50 day simple moving average is $437.19 and its two-hundred day simple moving average is $452.38. The stock has a market capitalization of $112.95 billion, a P/E ratio of 26.40, a PEG ratio of 1.86 and a beta of 0.30.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings results on Monday, May 4th. The pharmaceutical company reported $4.47 EPS for the quarter, beating analysts’ consensus estimates of $4.24 by $0.23. Vertex Pharmaceuticals had a net margin of 35.51% and a return on equity of 23.86%. The business had revenue of $2.99 billion for the quarter, compared to analysts’ expectations of $2.99 billion. During the same period last year, the business earned $4.06 earnings per share. The business’s quarterly revenue was up 8.3% on a year-over-year basis. As a group, equities analysts expect that Vertex Pharmaceuticals Incorporated will post 17.02 earnings per share for the current fiscal year.

Key Headlines Impacting Vertex Pharmaceuticals

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Vertex announced new data on CASGEVY showing clinical benefits in patients ages 5 and older with severe sickle cell disease or transfusion-dependent beta thalassemia, including pediatric data consistent with the therapy’s profile in older patients. The company also said it is making additional global regulatory submissions, which could expand the drug’s commercial opportunity. Article Title
• Positive Sentiment: Several recent items point to supportive Wall Street views, including a “Moderate Buy” consensus and multiple higher price targets, suggesting analysts still see upside despite the stock’s recent strength.
• Neutral Sentiment: Vertex presented at the Goldman Sachs Global Healthcare Conference, but no major new financial guidance or pipeline surprise was highlighted in the available summary. Article Title
• Neutral Sentiment: A senior executive sold shares under a pre-arranged 10b5-1 plan. While this can draw attention, the sale appears routine rather than a sign of negative business developments. Article Title
• Negative Sentiment: Erste Group trimmed its FY2027 EPS estimate for Vertex slightly, which may have limited enthusiasm a bit, though the change was modest and the outlook remains above current-year consensus. Article Title

Wall Street Analyst Weigh In

VRTX has been the subject of a number of recent research reports. Wall Street Zen lowered Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, May 30th. Bank of America raised their target price on shares of Vertex Pharmaceuticals from $571.00 to $598.00 and gave the stock a “buy” rating in a report on Tuesday, March 10th. Stifel Nicolaus raised their target price on shares of Vertex Pharmaceuticals from $445.00 to $466.00 and gave the stock a “hold” rating in a report on Friday, February 13th. Royal Bank Of Canada raised their target price on shares of Vertex Pharmaceuticals from $541.00 to $543.00 and gave the stock an “outperform” rating in a report on Tuesday, May 5th. Finally, Sanford C. Bernstein cut their target price on shares of Vertex Pharmaceuticals from $577.00 to $572.00 and set an “outperform” rating on the stock in a report on Tuesday, May 5th. Twenty-two analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, Vertex Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $555.91.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Motiv8 Investments LLC bought a new position in shares of Vertex Pharmaceuticals in the fourth quarter worth approximately $26,000. Swiss RE Ltd. purchased a new position in Vertex Pharmaceuticals during the 4th quarter valued at $28,000. Eagle Bay Advisors LLC purchased a new position in Vertex Pharmaceuticals during the 4th quarter valued at $29,000. IMG Wealth Management Inc. increased its position in Vertex Pharmaceuticals by 277.8% during the 4th quarter. IMG Wealth Management Inc. now owns 68 shares of the pharmaceutical company’s stock valued at $31,000 after purchasing an additional 50 shares during the period. Finally, Colonial Trust Co SC increased its position in Vertex Pharmaceuticals by 118.8% during the 3rd quarter. Colonial Trust Co SC now owns 70 shares of the pharmaceutical company’s stock valued at $27,000 after purchasing an additional 38 shares during the period. Institutional investors own 90.96% of the company’s stock.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.